New Cerebrospinal Fluid Cancer Tests Will Launch October 12
Houston patients and others in the U.S. will gain access to molecular profiling tests for CNS tumors and malignancies.
Updated on Oct. 6, 2026 in Cancer
Live Poll
Do you believe advanced genetic profiling is essential for improving cancer treatment results?
Cerenome is set to release two new molecular profiling tests on October 12, 2026, designed to analyze cancer-related genes and transcripts within cerebrospinal fluid. These tests aim to assist clinicians in identifying specific molecular abnormalities associated with complex central nervous system and hematologic cancers.
Why it matters
These tools expand diagnostic options for primary CNS tumors and metastatic solid tumors by identifying genetic mutations that inform clinical decision-making. Access to this level of molecular detail can help physicians better characterize the nature of a malignancy within the central nervous system.
A study in The Journal of Liquid Biopsy analyzed 1,391 cerebrospinal fluid specimens and identified cancer-related molecular findings in 78.4% of cases. The new tests utilize DNA and RNA sequencing on this fluid, though they have not yet been cleared or approved by the FDA.
The players
Cerenome
A diagnostics company focused on developing molecular profiling tests for central nervous system tumors and hematologic malignancies.
Genomic Testing Cooperative
A laboratory organization that provides DNA and RNA sequencing along with bioinformatics analysis for cancer research and clinical testing.
CNSide Diagnostics
The administrative entity managing the ordering process, results delivery, physician support, and billing for the CNSide testing platform.
The details
The tests function by sequencing cell-free DNA to identify sequence variants, copy-number alterations, and gene fusions, while simultaneously using RNA sequencing to analyze over 1,600 transcripts. Genomic Testing Cooperative manages the technical bioinformatics and sequencing, while CNSide Diagnostics oversees results delivery and physician support. This dual-approach method allows for a more comprehensive molecular picture of tumors residing in or spreading to the central nervous system.
Timeline
Tests were first performed in 2020.
The collaboration with Genomic Testing Cooperative was announced in July 2026.
The official commercial launch announcement occurred on October 6, 2026.
The tests become available for ordering on October 12, 2026.
Health Landscape
This development aligns with the shift toward liquid biopsies as a complement to traditional diagnostic methods for central nervous system malignancies. It marks a broader movement to utilize cerebrospinal fluid to map the genetic architecture of tumors that are otherwise difficult to sample.
If you or a loved one are managing a primary CNS tumor or metastatic solid tumor, these tests may offer new insights into the genetic makeup of the malignancy. Discuss with your physician whether molecular profiling of cerebrospinal fluid is an appropriate addition to your current care plan.
The takeaway
Molecular profiling of cerebrospinal fluid provides a new method for identifying cancer-related genetic variants in central nervous system tumors. Patients should talk to their oncology team to determine if molecular testing is a relevant step in their specific diagnostic or treatment journey.
Further reading
Learn more about the latest innovations in Cancer care and detection.
More information
For further technical specifications, view the CNSide diagnostics platform information.
Live Poll
Do you believe advanced genetic profiling is essential for improving cancer treatment results?
